

Morphle Labs secures \$5 M to revolutionise cancer diagnostics with Physical AI

25 November 2025 | News

Funding to accelerate market & team expansion, scale manufacturing, and deepen tech & IP leadership



Morphle Labs, a Bengaluru-based deep-tech healthcare automation startup building next-generation robotic and imaging systems for cancer diagnostics, has raised \$5 million in a Series A round, by Inflexor Ventures.

The funding will enable the company to accelerate global market expansion, scale manufacturing for its flagship products RoboTome® and MorphoLens, invest in global regulatory approvals, and deepen its technology and IP leadership as it expands into major international markets.

Founded in 2017, Morphle Labs is addressing one of the most underserved but critical aspects of healthcare: automation in histopathology, the core of cancer diagnostics.

The company's flagship platform, RoboTome®, is the first robotic microtome of its kind, capable of slicing biopsy blocks at over twice the speed of an experienced histotechnologist while delivering unmatched consistency in section quality, a critical requirement for downstream diagnostics. Its complementary platform, MorphoLens, is a high-throughput slide scanner that digitises 100+ slides per hour through robust optics and Al-driven imaging, enabling remote pathology and scalable diagnostic operations. Together, the platforms automate some of the most complex and historically manual steps in histology,

forming an end-to-end workflow that improves speed, reliability, and clinical readiness. Morphle has filed 80+ patents across robotics, optics, embedded systems, and imaging, underscoring its deep R&D culture.

Commenting on the fundraise, Rohit Hiwale, Founder & CEO, Morphle Labs, said, "With this funding we will also be expanding our team, while solving some extremely valuable problems for mankind, we are on a mission to improve talent density across Robotics & computer vision."

With the newly secured funding, Morphle Labs will scale manufacturing to meet accelerating global demand for RoboTome® and MorphoLens, expand its IP portfolio across international jurisdictions, and push forward on global regulatory certifications essential for medical device commercialisation. The company also plans to grow its engineering, research, and product teams across robotics, vision systems, optics, hardware development, medical-grade software, and compliance.